Hepion Pharmaceuticals, Inc.

NASDAQ:HEPA

0.63 (USD) • At close November 4, 2024
Bedrijfsnaam Hepion Pharmaceuticals, Inc.
Symbool HEPA
Munteenheid USD
Prijs 0.634
Beurswaarde 3,678,968
Dividendpercentage 0%
52-weken bereik 0.553 - 4.47
Industrie Biotechnology
Sector Healthcare
CEO Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D.
Website https://www.hepionpharma.com

An error occurred while fetching data.

Over Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease;

Vergelijkbare Aandelen

Pro-Dex, Inc. logo

Pro-Dex, Inc.

PDEX

40.63 USD

MEI Pharma, Inc. logo

MEI Pharma, Inc.

MEIP

3.06 USD

Medicenna Therapeutics Corp. logo

Medicenna Therapeutics Corp.

MDNA

0.157 USD

Black Diamond Therapeutics, Inc. logo

Black Diamond Therapeutics, Inc.

BDTX

2.99 USD

Molecular Templates, Inc. logo

Molecular Templates, Inc.

MTEM

0.457 USD

Solid Biosciences Inc. logo

Solid Biosciences Inc.

SLDB

5.66 USD

Biotricity, Inc. logo

Biotricity, Inc.

BTCY

0.357 USD

Purple Biotech Ltd. logo

Purple Biotech Ltd.

PPBT

2.97 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)